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1. Introduction
   Hepatitis B virus (HBV) is one of the most important viruses, 
which infects hepatocytes in livers and leads to hepatocellular 
carcinoma. HBV is spherical virus with 22 nm diameter and has 
a partially double-stranded and relaxed circular DNA genome[1]. 
Four open reading frames encode structural proteins of the virion, 
the central body of the virus, a small transcription activator (X) 
and a large polymerase (P), which is responsible for the reverse 
transcriptase and Ribo nuclease H[2]. The C gene contains two start 
codons that encode hepatitis B core antigen and HBe protein, which 
will be converting to solution hepatitis Be antigen (HBeAg)[3]. HBV 
is transmitted through blood transfusion, sexual contact and also can 
cause acute or chronic diseases, especially in infants, and 5%–10% 
of people suffering from chronic hepatitis B (CHB) after the primary 
disease[4,5]. Almost one-third of people with chronic active hepatitis 
show liver failure and cirrhosis. The other two thirds of people 
having temporary chronic hepatitis and primary hepatocellular 
carcinoma can be attributed to chronic HBV infection[6]. The World 
Health Organization estimates that there are about 350 million 
carriers of chronic HBV in the world that 15%–40% of their lives 
are in danger due to the possibility of the disease progression 
to cirrhosis and liver cancer. In Iran, about 1.2%–9.7% of HBV 
infection has been reported in different areas[7], and 1.5–2.5 million 
people in Iran suffer from HBV infection[8]. It should be mentioned 
that the incidence rate of mutations in HBV infection is ten times 
more than other DNA viruses. According to different studies, anti-
retroviral therapy is the most important factor in the creation of 
mutations in the virus reverse transcription/polymerase gene (the 
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most important target for antiviral drugs[9]. A common treatment 
for patients with CHB is the combination of interferon alpha and 
the nucleoside/nucleotide analogous such as lamivudine, entecavir, 
telbivudine, adefovir and tenofovir. The application of these drugs is 
a big step in the treatment of CHB patients[10]. However, one problem 
associated with these drugs is the emergence of drug resistance in 
mutant strains[11]. Different types of mutations in the polymerase 
region (POL) have been described, such as mutations in tyrosine-
methionine-aspartate-aspartate and leucine–leucine–alanine–glutamine 
regions, rtN236T, rtM204I, rtV84M and rtM194T. The commonest 
drug resistance is tyrosine-methionine-aspartate-aspartate motif 
mutation which possesses lamivudine resistance[12]. Mutations 
in rtA194T can cause resistance to tenofovir disoproxil fumarate 
(TDF) which is an acyclic nucleotide analogue relating to adefovir 
dipivoxil[13]. In 2008, tenofovir got the approve for the treatment 
of CHB, and it is available for the treatment of HIV infection. 
Tenofovir is superior to adefovir for the HBV DNA suppression, 
HBeAg seroconversion and the normalization of alanin amino 
transferase (ALT)[14]. PCR sequencing, restriction fragment length 
polymorphisms, INNO-LiPA and matrix-assisted laser desorption/
ionization time of fight-mass spectrometry are developed to detect 
resistant mutations. The zip nucleic acid (ZAN) probe assay was used 
for detecting rtA194T mutation in POL region of HBV that published 
before[15]. HBV with rtA194T mutation reduces the susceptibility 
to tenofovir combining with lamivudine resistance rtM204V and 
rtL180M mutations in vitro[16,17]. Also, rtA181T and rtN236T 
mutations associated with adefovir resistance in in-vitro studies have 
showed the reduction in the susceptibility to tenofovir[18]. In this 
study, a sensitive real-time fluorescent quantitative PCR using ZNA 
probes was used to detect tenofovir-resistant mutants in chronic HBV 
patients with the history of long-term antiviral therapy in Kerman, 
southeast of Iran. 
2. Materials and methods
2.1. Patients
   In retrospective study in our laboratory (Virology Laboratory 
of the Besat Specialist Clinic, Kerman, Iran), 64 patients with 
CHB including 36 men and 28 women with the mean age of 42 
years ranging from 21–63 years were enrolled from October 2013 
to March 2014. The treatment was based on the combination of 
the serum HBV DNA level, serum ALT level and the histological 
grade and stage of the underlying liver disease. Exclusion criteria 
included having severe illness, organ transplantation, treatment 
with corticosteroids, any liver disease not due to hepatitis B, and 
seropositivity for HIV or hepatitis C or hepatitis D virus.
2.2. Serological analysis
   ALT and aspartic amino transferase (AST) were tested in blood 
samples from the patients with CHB. hepatitis B surface antigen 
(HBsAg) and HBeAg were tested with immunoassay method 
and ELISA and then both of them were evaluated with electro-
chemi-luminescence method (ECL). Our serological markers were 
analyzed by HBsAgII HBeAg Elecsys and Cobas analyzers (Roche, 
Germany). ELISA method was carried out with an automatic plate 
washer (Bioscience, Tian Jin, China) and PETECK96-II Detection 
System (Bioscience) was used to read relative light units at 450 nm 
(Figure 1).
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Figure 1. Comparison of serological tests in two different methods 
(Elecsys and ELISA) [P < 0.05, 95% confidence interval (CI): 25–45].
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2.3. HBV DNA level 
   By RIBO-Prep kit (ILS, Russia), HBV DNA was extracted from 
plasma and quantified via real-time PCR by the commercial kit (ILS, 
Russia). In our method, the real-time PCR had a lower limit of 30 
copies/mL.
2.4. Detection of rtA194T mutations
   Specific primers and probes designed for HBV polymerase region 
to determine rtA194T mutation in nt-194 of the POL gene were 
detected by using Beacon designer software (version 8 primer, 
Biosoft, USA) (Table 1). Metabion Company (Metabion International 
AG, Germany) synthesized primers and probes and real time ZNA 
probe method was developed for tenofovir-resistant mutants. The 
quantitative real time PCR was done with the Rotor-Gene 6000 
(Corbett Research, Australia) and the condition starts with 15 min 
with hot start Taq DNA polymerase at 95 °C followed by 45 cycles at 
95 °C for 10 s and 60 °C for 30 s. 
Table 1
Sequence primers and probes for the detection of tenofovir resistance.
Name Sequence
Forward primer CCGCTGTTACCAATTTTC
Reverse primer GCCCATGAAATGTAAAGA
Wild type probe (A) FAM-TTGGGTATACATTTAACCCCTACCAAA-BHQ1
Mutant probe (T) JOE-TTGGGTATACATTAAACCCCTACCAAA-BHQ1
2.5. Statistical analyses
   To analyze the data, Chi-square and Fisher’s exact tests were used 
by SPSS 15.0 software (SPSS Inc, Chicago; USA) and P < 0.05 were 
considered significant.
3. Results
   A total of 64 patients with CHB were selected from October 2013 
to March 2014. Among them, 36 (56.2%) were men and 28 (43.8%) 
were women. The age of patients was (42.72 ± 10.90) years. The 
levels of ALT and AST were (123.30 ± 13.80) and (125.62 ± 15.06) 
IU/mL, respectively. We categorized HBV DNA load from 30 to 
more than 109 copies/mL. Twenty-six (40.6%) patients had less than 
30 copies/mL DNA load. HBsAg was tested by ELISA method, and 
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data showed that 54 (83.9%) were positive and 10 (16.1%) were 
negative. Also, via ECL method, 51 (79.7%) were positive and 13 
(20.3%) were negative (Figure 2). HBeAg were tested by ELISA, 5 
(7.9%) were positive and 59 (92.1%) were negative but via ECL 14 
(21.9%) were positive and 50 (78.1%) were negative. The incidence 
rate of rtA194T was performed with real-time PCR. The presence of 
the mutations showed that 13 (20.3%) were mutant and 51 (79.7%) 
belonged to the wild type (Figure 3). The incidence rate of rtA194T 
in males and females were 5 (38.5%) and 8 (61.5%), respectively. 
But there was no significant relation between gender and rtA194T 
mutation. Serum AST and ALT related to rtA194T mutants showed 
that the level of ALT was (196 ± 56) IU/mL and in wild variants it 
was (104 ± 15) IU/mL. Therefore no differences was seen in these 
category (P = 0.48). As for AST, it was (214 ± 59) IU/mL in mutant 
strains and (102 ± 17) IU/mL in wild type strains. There was no 
significant relation between AST and rtA194T mutation (P = 0.139) 
(Figure 4). Our results showed that most of mutations were in more 
than 109 HBV DNA loads which may be resistant to the antiviral 
therapy. Therefore, there was a significant correlation between 
HBV DNA load and rtA194T mutation. This study showed that all 
of the mutants were in HBsAg positive samples, therefore rtA194T 
mutation had significant relation between HBsAg and mutation in 
rtA194T (P = 0.04). Six (46.2%) of the mutations were in HBeAg 
negative cases (P = 0.02). HBeAg status had significant relation with 
rtA194T mutation.
Figure 2. HBV load in mutant and wild type groups (P < 0.05, 95% CI: 
101–109).
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Figure 3. Comparison of HBsAg and HBeAg in mutant and wild type 
groups (P < 0.05, 95% CI: 20–55). 
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Figure 4. Comparison of HBsAg and HBeAg in different HBV DNA load 
(P < 0.05, 95% CI: 101–109).
4. Discussion
   Chronic infection with HBV causing liver diseases with morbidity 
and mortality has become an important global health problem[19]. 
The drug therapy in HBV-infected patients can limit the progression 
of the disease through the viral replication[8]. In CHB cases, the 
rate of spontaneous clearance of HBsAg is 0.5%–2%[20], and 
10%–15% of the cases loss HBeAg and serum HBV DNA[21]. 
In most individuals, long-term antiviral treatment raises the risk 
of drug-resistant mutants which is associated with polymerase 
gene mutations. This mutation might be raised by high HBV 
viral load and ALT levels[4,22]. Different anti-HBV agents may 
be very important to help patients who are drug-resistant[23]. 
Quantitative real-time PCR is able to detect any resistant mutants 
in HBV populations[15,24]. TDF is an acyclic nucleotide analogue 
that is related to adefovir dipivoxil[25]. It has been shown that 
tenofovir is better than adefovir in terms of HBV DNA suppression, 
seroconversion of HBeAg and ALT normalization[26]. Tenofovir 
resistance is made with mutation in nt-194 location of polymerase 
gene, an adenine (A) substitution with a thymine (T), therefore a 
change formation in the polymerase gene cause that tenofovir has 
no affinity to polymerase and virus continue replication[27]. This 
is the first study ever done Kerman and more information is not 
available about HBV resistance to TDF. In the current study, the 
rate of rtA194T mutation was 20.3%, which is higher than that 
in the study conducted in Germany showing 4.6% of patients has 
mutation. Our study also determined that the association of rtA194T 
mutation with HBV DNA levels is significant. This mutation was 
seen in higher level of DNA load (109 copies/mL). Sheldon et al.[28] 
showed that after treatment, HBV DNA load reduced but after 40 
weeks because of the occurrence of mutation and drug resistance, 
HBV load were increased and ALT level increased suddenly. In 
our study, the mean of ALT was 196 IU/mL which was higher 
than that in the wild variants[28]. In the same study, all mutations 
were seen in HBeAg positive patients, but in our study 71.8% of 
mutants were seen in HBeAg negative status. In another study, after 
treatment with TDF, HBeAg remained negative with detectable anti-
HBeAg. Patients with HBsAg level < 100 IU/mL during an ALT 
flare after antiviral discontinuation achieved sustained response, 
but in our study, all of mutants were seen in HBsAg positive[29,30]. 
In conclusion, biochemical markers such as HBeAg, serum ALT 
level and HBV viral load were used in the diagnosis in patients 
with HBV infection. The sign of response to antiviral therapy is 
ALT normalization and serum HBV DNA suppression and if virus 
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is resistant, it can be proposed that some mutations in active site of 
antiviral drug may happen. In this study, the amount of mutations 
were evaluated according to the rise of serum HBV DNA titer or ALT 
level. In addition, high sensitive and specific real-time PCR method 
for the detection of new mutation of rtA194T to evaluate tenofovir 
resistance was used for better decision-making and future helpful 
therapy for patients.
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